Lessons from Monte Carlo Models: Why Drug Development is Hard
DrugBaron
FEBRUARY 16, 2024
So what does the game look like to a late-stage investor or a pharma company head of R&D thinking about portfolio prioritisation? By contrast, if you behave like an early-stage investor with a good quality pharma company pipeline, you will likely kill value by under-investing or stopping projects that have real value.
Let's personalize your content